리커전 파마슈티컬스(RXRX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.83 (+8.19%), 시가총액 $1.56B, 52주 최저~최고 $2.84 ~ $6.79.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4
리커전 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
리커전 파마슈티컬스의 현재 주가는 $3.83 (+8.19%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
리커전 파마슈티컬스의 시가총액은 약 $1.56B입니다.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, d